Drugs / FK-PC101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06636682 | Oct 2024 → Feb 2027 expected | prostate adenocarcinoma | Cellvax Therapeutics Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FK-PC101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06636682 ↗ |
| Modality | Vaccine | “FK-PC101 is an autologous cellular vaccine” NCT06636682 ↗ |